Variable | Categorisation | Control | Celecoxib |
---|---|---|---|
 |  | Number = 15 | Number = 22 |
Mean age ± SD (years)a | 57 ± 12 | 51 ± 12 | |
Histological tumour typeb | |||
 | Invasive ductal carcinoma | 13 (87%) | 19 (86%) |
 | Invasive lobular carcinoma | 2 (13%) | 3 (14%) |
Tumour sizec | |||
 | pT1 | 10 (67%) | 8 (36%) |
 | pT2 | 5 (33%) | 13 (59%) |
 | pT3 | 0 (0%) | 1 (5%) |
Lymph node statusc | |||
 | Negative (pN0) | 11 (73%) | 10 (45%) |
 | Positive (pN1-3) | 4 (27%) | 12 (55%) |
Tumour graded | |||
 | G1 | 5 (33%) | 1 (5%) |
 | G2 | 4 (27%) | 7 (32%) |
 | G3 | 6 (40%) | 14 (63%) |
Oestrogen receptor statuse | |||
 | ER positive | 11 (73%) | 19 (86%) |
 | ER negative | 4 (27%) | 3 (14%) |
Progesterone receptor statuse | |||
 | PgR positive | 10 (67%) | 17 (77%) |
 | PgR negative | 5 (33%) | 5 (23%) |
HER2 statusf | |||
 | HER2 positive | 3 (20%) | 3 (14%) |
 | HER2 negative | 12 (80%) | 18 (82%) |
 | Unknown | 0 (0%) | 1 (5%) |